Arcturus Therapeutics Holdings Inc. (ARCT) |
|
16.16 0.42 (2.67%)
|
07-02 16:01 |
|
Open: |
15.7 |
Pre. Close: |
15.74 |
|
High:
|
16.56 |
Low:
|
15.2265 |
|
Volume:
|
683,451 |
Market Cap:
|
427(M) |
|
|
|
|
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
16.58 - 16.64 |
16.64 - 16.71 |
|
Low:
|
15.07 - 15.14 |
15.14 - 15.21 |
|
Close:
|
16.04 - 16.15 |
16.15 - 16.27 |
|
Technical analysis |
as of: 2022-07-01 4:20:06 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 20.48 One year: 24.7 |
| Support: |
Support1: 11.69 Support2: 9.73 |
| Resistance: |
Resistance1: 17.54 Resistance2: 21.14 |
| Pivot: |
14.61 |
| Moving Average: |
MA(5): 15.7 MA(20): 15.45 
MA(100): 20.79 MA(250): 32.63 |
| MACD: |
MACD(12,26): -0.7 Signal(9): -1 |
| Stochastic oscillator: |
%K(14,3): 73.3 %D(3): 58.7 |
| RSI: |
RSI(14): 49.6 |
| 52-week: |
High: 65 Low: 11.69 |
| Average Vol(K): |
3-Month: 810 (K) 10-Days: 1,010 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ARCT ] has closed below upper band by 21.1%. Bollinger Bands are 39.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sat, 02 Jul 2022
ArbitrageCT (ARCT): How Does the Chart Look Saturday? - InvestorsObserver
Tue, 28 Jun 2022
EACO committed to firm management of communication services in EAC - The Citizen
Tue, 28 Jun 2022
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Sat, 11 Jun 2022
ArbitrageCT (ARCT) Rises 24.48% Saturday: What's Next for This Very Bullish Rated Crypto? - InvestorsObserver
Mon, 06 Jun 2022
Arcturus: Potential Based On Rare Disease Therapy ARCT-810 (NASDAQ:ARCT) - Seeking Alpha
Wed, 11 May 2022
These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
26 (M) |
|
% Held by Insiders
|
2.271e+007 (%) |
|
% Held by Institutions
|
13.8 (%) |
|
Shares Short
|
2,590 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.0166e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
641.3 |
|
Return on Equity (ttm)
|
-29.2 |
|
Qtrly Rev. Growth
|
1.236e+007 |
|
Gross Profit (p.s.)
|
57.99 |
|
Sales Per Share
|
-23.8 |
|
EBITDA (p.s.)
|
4.51095e+006 |
|
Qtrly Earnings Growth
|
-7.6 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-135 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.68 |
|
Price to Cash Flow
|
4.5 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
3.05e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-11-15 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
